Linagliptin applicable across wide group of T2DM patients- Latest Indian Position Paper - Video

Published On 2023-09-30T11:30:21+05:30 | Updated On 30 Sept 2023 4:29 PM IST

Overview

As per the latest Indian position statement released in the Journal of the Association of Physicians of India, August 2023 issue, Linagliptin therapy is simplifying the management of T2DM with efficacy & applicability across a wide range of patients.

Key expert opinions from this Position paper include:

1. 94.3% of Healthcare Professionals (HCPs) opined that a single 5 mg once daily dosing of linagliptin across diverse T2DM patient profiles, irrespective of cardiac, renal, or hepatic comorbidities, eases up management of T2DM

2. Linagliptin is used in both Drug naïve and uncontrolled T2DM patients.

Linagliptin has multiple clinical and safety advantages across a wide group of T2DM patients, making it potentially an evergreen oral anti-diabetic agent and combination of Linagliptin & Dapagliflozin and Evergreen DUO.

Reference:

Mithal, A., et.al. (2023). Simplifying Type 2 DM Care with Linagliptin: A Position Paper. The Journal of the Association of Physicians of India, 71(8), 11–12. https://doi.org/10.59556/japi.71.0324

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751